NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
51991-0992-28 | 51991-0992 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 28, 2025 | In Use | |
72266-0128-01 | 72266-0128 | Melphalan hydrochloride | Melphalan hydrochloride | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Sep 23, 2019 | In Use | ||
69097-0368-40 | 69097-0368 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | May 4, 2018 | In Use | |
63187-0256-20 | 63187-0256 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 1, 2017 | In Use | |
00002-6216-54 | 00002-6216 | Abemaciclib | Verzenio | 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct 6, 2017 | In Use | |
72606-0558-01 | 72606-0558 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 6, 2020 | In Use | |
63187-0256-30 | 63187-0256 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 1, 2017 | In Use | |
55150-0125-02 | 55150-0125 | Ondansetron Hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 21, 2012 | In Use | |
00115-1408-01 | 00115-1408 | Methyltestosterone | Methyltestosterone | 10.0 mg/1 | Hormonal Therapy | Androgen | Oral | Sep 21, 2015 | In Use | ||
69097-0927-35 | 69097-0927 | Palonosetron hydrochloride | Palonosetron hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Mar 23, 2018 | In Use | |
71335-2500-09 | 71335-2500 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 23, 2024 | In Use | |
00024-0654-01 | 00024-0654 | Isatuximab | Sarclisa | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Mar 2, 2020 | In Use | |
55150-0299-01 | 55150-0299 | Fosaprepitant dimeglumine | Fosaprepitant dimeglumine | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jan 12, 2021 | In Use | |
55150-0355-01 | 55150-0355 | IRINOTECAN HYDROCHLORIDE | IRINOTECAN HYDROCHLORIDE | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 11, 2022 | In Use | |
00024-5840-01 | 00024-5840 | ziv-Aflibercept | Zaltrap | 100.0 mg/4mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug 3, 2012 | In Use | |
00054-0249-12 | 00054-0249 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2018 | In Use | |
81298-8110-01 | 81298-8110 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan 1, 2022 | In Use | |
59923-0723-90 | 59923-0723 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 1, 2020 | In Use | |
00409-0201-02 | 00409-0201 | DOCETAXEL ANHYDROUS | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 17, 2011 | In Use | |
55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov 18, 2010 | In Use | |
00409-0302-01 | 00409-0302 | Topotecan | Topotecan | 1.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb 21, 2011 | In Use | |
00409-1061-01 | 00409-1061 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jun 20, 2022 | In Use | |
00069-0197-30 | 00069-0197 | dacomitinib | Vizimpro | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct 4, 2018 | In Use | |
55566-8303-01 | 55566-8303 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Mar 2, 2009 | In Use | |||
59651-0487-01 | 59651-0487 | PREDNISONE | PREDNISONE | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 28, 2022 | In Use |
Found 11398 results — Export these results